Introduction
The MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) gene has been identified as a myelomaassociated oncogene which is activated at the transcriptional level as a result of t(6;14)(p25;q32) chromosomal translocation and by virtue of its juxtaposition to the 3Ј ␣ enhancer locus of the immunoglobulin heavy chain gene (IgH). 1 It belongs to the interferon regulatory factor (IRF) family, which is generally induced by interferon (IFN) and plays important roles not only in resistance against viral infections but also in cellular proliferation and survival. [2] [3] [4] Its expression is restricted to cells in lymphocytic and melanocytic lineages. [5] [6] [7] Furthermore, MUM1 expression was found to be highest in plasma cells among B lineage and in activated T cells among T lineage lymphocytes as determined by expression analysis of various hematopoietic cell lines. 1, [5] [6] [7] The physiological function of MUM1 is still unknown except that it works in cooperation with PU.1 as a transcriptional regulator in lymphCorrespondence: S Iida, Second Department of Internal Medicine, Nagoya City University Medical School, Kawasumi 1, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, Japan; Fax: 81-52-852-0849 Received 1 October 1999; accepted 15 November 1999 oid cells. [6] [7] [8] [9] [10] [11] It is of interest that absence of the MUM1 function in MUM1−/− mice results in extremely low levels of serum immunoglobulins and in marked reduction of both activated lymphocytes and plasma cells. These findings suggest prerequisite roles for MUM1 in lymphocyte activation and in terminal B cell differentiation. 12 In order to identify the roles of the MUM1 gene in normal lymphocyte development and in lymphomagenesis, we used specific goat antiserum generated against the MUM1 protein to study the expression of the MUM1 protein in reactive lymphoid hyperplasia (representative of nearly normal lymph nodes) and their malignant counterparts, ie lymphoma tissues.
Materials and methods

Specific antibodies used in this study
The specific polyclonal and monoclonal antibodies used in this study are shown in Table 1 . An affinity-purified anti-ICSAT/MUM1/IRF4 (M-17) goat serum (Santa Cruz Biotechnology) was originally generated by immunizing goats with a C-terminal (amino acids, 433-449) peptide of mouse origin. It reacts with MUM1 of mouse, rat and human origins, although it does not cross-react with other members of the IRF family of proteins.
Cell lines and tissue samples
The various hematopoietic cell lines used in this study are shown in Table 2 . Detailed characteristics of these cells have been reported previously. 1, 13 Formaline-fixed, paraffinembedded lymph node tissues obtained from patients with reactive lymphoid hyperplasia and those of histologically well-characterized lymphomas were subjected to immunostaining using anti-ICSAT (M-17) goat serum (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Diagnosis of the lymphoma samples was reviewed by two independent hematopathologists (authors HI and SN) and classified according to the Revised European-American Classification of Lymphoid Neoplasms (REAL).
14 Double immunostaining of CD38 and MUM1 was performed by using 2 m-thick acetone-fixed lymph node tissues.
Establishment of the MUM1 transfectant
Either pHebo-CMV-Neo or pHebo-CMV-MUM1-Neo expression constructs were transfected into Burkitt's lymphoma cell line P3HR-1, with silent MUM1 expression at the mRNA level. In brief, 1 × 10 7 cells were electroporated in 300 l of plain RPMI 1640 medium at a voltage of 250 V and a capacitance of 500 F with the aid of a Biorad Gene Pulser II (Biorad, Hercules, CA, USA). To obtain stable transfectants in bulk, the cells were cultured for 14 days in the presence of G418 at a final concentration of 1600 g/ml.
Immunoblotting analysis
Cell pellets prepared from various cell lines were resuspended in 1× Laemmli sample buffer and boiled for 5 min. Protein lysates derived from 1 × 10 6 cells were fractionated on to a 7.5% SDS acrylamide gel and transferred to a nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany). After blocking in Tris-buffered saline (TBS)-0.2% Tween with 5% dried milk, the blots were incubated at 20°C for 1.5 h with a 1/500 M-17 serum in TBS-0.1% Tween and 3% bovine serum albumin, followed by incubation with 1/5000 anti-goat IgG, horseradish peroxidase-linked antibody (Amersham, Buckinghamshire, UK) in TBS-0.1% Tween and 5% milk. Reactive bands were detected by using an ECL system (Amersham).
Immunostaining
Immunoreactions for MUM1 were performed after high temperature antigen retrieval for 4 min in a pressure cooker with slides dipped in 0.01 m sodium citrate (pH 6.0) buffer. The sections were then incubated with 1/200 diluted M-17 goat serum at room temperature for 1 h. The MUM1 protein was detected with the streptavidin-biotin complex method (sABC). Double immunostaining was also performed for hyperplastic lymph nodes and some lymphoma tissues fixed in 10% formaldehyde or in acetone by using a modified version of the AMeX method in order to evaluate coexpression of the MUM1 with representative B and T cell surface markers. 15 Doublestaining with the 3, 3Ј diaminobenzidine tetrahydrochloride (DAB) method visualized cell surface markers such as CD3, CD45RO, CD20, CD23 and CD38 in brown in contrast to MUM1 visualized in blue with True Blue (tetramethylbenzidine) (KPL, Gaithersburg, MD, USA).
Activation of peripheral blood lymphocytes by mitogenic stimuli
Peripheral blood mononuclear cells (PBMCs) were fractionated by means of Ficoll-Hypaque centrifugation and washed twice with phosphate-buffered saline (PBS). The total PBMCs were incubated in RPMI 1640 medium with 10% FBS for 48 h at 37°C at 5% CO 2 in the presence or absence of 1/100 volume of either phytohemmagglutinin (PHA) or pokeweed mitogen (PWM) solution (GIBCO BRL, Tokyo, Japan). These cells were then attached on to glass slides with the aid of a cytospin (Shandon, Pittsburgh, PA, USA), rapidly air-dried, fixed in cold 1:1 acetone/methanol and frozen until use for immunostaining.
Results
M-17 anti-ICSAT goat serum specifically detects the MUM1 protein
Specificity of the M-17 antiserum was assessed in P3HR-1 cells transfected with pHebo-CMV-MUM1-Neo. Immunoblot analysis detected an appoximately 50 kDa. MUM1 product, whose molecular weight was predicted from the composition of its amino acid sequence, only in P3HR-1-CMV-MUM1-Neo cells but not in P3HR-1-CMV-Neo control cells which are negative for MUM1 mRNA expression (left panel of Figure 1a ). In line with this result, the MUM1 protein was stained in only a fraction of the P3HR-1-CMV-MUM1-Neo cells (Figure 1b) . The positive staining was predominantly observed as punctate dots in the nuclei, although weak staining was also found in cytoplasm, probably due to the excessive amount of protein.
To further confirm the specificity of the detection, competitive binding with an immunizing synthesized peptide (amino acid 432-449) was carried out. Preincubation of the M-17 anti- 
Positive MUM1 staining observed in lymphocytic cell lines derived from mature B, plasma and activated T cells
Various hematopoietic cell lines were immunostained with the M-17 antiserum (data not shown). The nuclear MUM1 T cell and NK cell non-Hodgkin's lymphoma protein was detected only in the lymphocytic cell lines (Table  2) , which was consistent with the result obtained from immunoblot analysis as shown in the right panel of Figure 1a . Among the B cell lines, MUM1 was present in cells from mature B cell through to the plasma cell stages, although some mature B cell lines such as P3HR-1 and RAJI lacked its expression. As immunostaining caused all of the myelomaderived cell lines to show strong expression, overexpression observed in myeloma cells carrying t (6;14) at the level of the mRNA and of the protein could not be validated by this method. 1 Adult T cell leukemia/lymphoma (ATL/L)-derived T cell lines stained strongly for MUM1, while immature and other mature T cell lines did not.
Leukemia
T-LB 9 - - 0/9 (0%) LGL 7 - - 0/7 (0%) AILD 3 - - 0/3 (0%) ATL/L 3 - 2 2/5 (40%) ALCL 1 - 4 4/5 (80%) Unspecified 3 - 4 4/7 (57%) Hodgkin's disease Classical type NS 1 1 4 5/6 (83%) a MC - - 7 7/7 (100%) a L-rich - 1 - 1/1 (100%)
Induction of the MUM1 protein by lymphocyte activation
We tested the expression of MUM1 in peripheral blood mononuclear cells (PBMCs). Positive staining was visible in neither T nor B lymphocytes. PBMCs were then cultured for 48 h at a 1 × 10 5 /ml concentration in RPMI 1640 medium containing 10% fetal bovine serum in the presence or absence of mitogens such as PHA and PWM. Immunostaining of the cells for CD25 antigen after a 48 h culture in the presence of mitogens confirmed their activation (data not shown), which resulted in moderate to strong nuclear expression of MUM1 in the majority of activated lymphocytes only when mitogens were added to the culture medium. Those MUM1
+ cells were ident-ified as belonging to both T and B cell origins by means of double-staining with CD3 or CD20 antigens (Figure 2) .
Distribution of the MUM1 + cells in reactive lymph nodes
The MUM1
+ cells in the reactive lymphoid tissues were predominantly seen in the light zone of the germinal centers (GC) (Figure 3a) . Examination of 11 different specimens revealed that the cells accounted for 7.9 ± 4.2% (as mean ± 1 s.d.) of the light zone mononuclear cells, and consisted of both plasma cells and centrocytes as identified by morphological observations. MUM1 also stained positive in a very small percentage of the interfollicular mononuclear cells scattered throughout the paracortex, which were thought to be plasma cells and immunoblasts. In all cases, MUM1 was localized in the nuclei and was not observed in the cytoplasm (Figure 3b) . Double-immunostaining of the lymph nodes, histologically diagnosed as affected by mild nonspecific chronic lymphadenitis, disclosed that the majority of the MUM1 + cells within the light zone of the GC were CD20
+ B cells and that the majority of CD45RO + T cells in the paracortex areas lacked MUM1 expression (Figure 3c and d) . Next, we investigated whether MUM1 is coexpressed with activated B cell markers such as CD23 and CD38 antigens. Double-staining demonstrated that MUM1 tended to be coexpressed with CD38 (Figure 3e ), but that CD23 was positive only in a fraction of the MUM1 + cells (Figure 3f ). No MUM1 staining was observed in histiocytes, follicular dendritic cells or interdigitating cells. In addition, T lymphocytes in the normal thymus showed no positivity for MUM1, at least in the three samples derived from patients of different ages.
MUM1 is frequently expressed in various subtypes of lymphomas of B and T cell origins
Overall MUM1 positivity in B and T/NK cell lymphomas was 46.6% (34/73) and 27.8% (10/36), respectively, with positivity defined as more than 20% of the tumor cells being stained (Table 3 and Figure 4 ). This cut-off value was determined on the basis of the mean + Only one case of lymphoplasmacytic lymphoma/ immunocytoma also showed strong positivity (data not included). All of the myeloma samples obtained from bone marrow showed high intensity for MUM1 staining (data not shown). These findings suggest to us that MUM1 is generally expressed in tumor cells originating from GC/post-GC B cells except for the B-CLL/SLL cases. Overall MUM1 positivity by subtype of B cell malignancy is summarized in Figure 5 . As Leukemia for the few cases with T/NK cell lymphoma, MUM1
+ neoplastic cells were observed in 40% (2/5) of ATL/L, 80% (4/5) of anaplastic large cell lymphomas (ALCL) and 57% (4/7) of unspecified peripheral T cell lymphomas (PTCL). T lymphoblastic lymphoma (T-LB), large granular lymphocyte/leukemia (LGL), including NK cell type and angioimmunoblastic T cell lymphoma (AILD), were negative for MUM1. In addition, it was of interest that most Hodgkin's disease cases, including those with nodular sclerosis (NS), mixed cellularity (MC) and lymphocyte-rich (L-rich), showed the presence of MUM1 
Discussion
We have demonstrated in this study the specific immunoreactivity of M-17 goat serum against the MUM1/IRF4 protein. To our knowledge, this is the first report describing the detailed locations of the MUM1/IRF4 protein in lymphoid tissues. As expected from its assumed function as a transcription regulatory factor, the location of this protein in lymphoid cells, like that of other members of the IRF family, was restricted to the nuclei in B and T lymphocytes. 2, 3, 16 MUM1 expression was also upregulated in human peripheral blood T and B lymphocytes as a result of mitogenic stimuli. This is consistent with previous findings showing that MUM1 expression is induced in mouse T cells and in Jurkat cells by antigen mimetic stimuli such as CD3 crosslinking and in mouse B cells by IgM crosslinking, lipopolysaccharide (LPS), and phorbol myristate acetate (PMA). 5 The findings obtained from knock-out mice also support the importance of MUM1/IRF4 in B cell activation, because in IRF4−/− mice the number of CD23 + B220 + cells is markedly reduced and B cell proliferation enhanced by IgM crosslinking or LPS is impaired. 12 Although the promoter sequences upstream from the first exon of the MUM1 gene differ in mouse and human, their roles in lymphocyte activation appear to be species-shared. 1, 5 In view of these findings, we double-stained MUM1 and CD23 or CD38 antigens as representatives of the B cell activation markers in reactive lymphoid tissues. To our surprise, only a fraction of the MUM1 + cells showed positivity for the CD23 antigens and Although pre-B cell lines such as BALL-1 and 697 were found to weakly express MUM1 mRNA in Northern analysis, 1 they showed a negative response to our staining, probably due to either the lower sensitivity of the staining method or the existence of a regulatory mechanism at the protein translation. Among the T cell lines, especially strong MUM1 expression was observed in ATL/L-derived cell lines, as previously reported, 6 probably because these cells phenotypically correspond to activated T cells expressing CD25 (Tac) antigen. Actually, when peripheral blood lymphocytes were used in our analysis, activated T cells stimulated by PHA also showed strong expression of the CD25 antigens when MUM1 became positive in these CD3 + T cells (data not shown). This appears to be of interest because the tax protein encoded by the HTLV-I genome has been reported to upregulate the transcription of the MUM1/IRF4/ICSAT gene, 6 so that MUM1 may play an important role in the tumorigenesis of ATL/L.
Most MUM1 + cells constituted a distinct topographic comLeukemia partment in the light zone of the GC in lymphoid tissues. This finding differs from others for NHL-associated oncoproteins such as BCL6, BCL2 and PAX-5 (BSAP), whose predominant compartments are located, respectively, in the GC, the mantle zone/apical portion of the light zone and the mantle zone. [17] [18] [19] In reactive lymphoid tissues, MUM1
+ cells accounted for a fraction of the light zone B cells with a variety of nuclear morphologies, plasma cells and an extremely small number of T cells located in the paracortex area. This, in conjunction with the MUM1 immunoreactivity in activated B cells, suggests to us that MUM1 becomes activated when GC/post-GC B cells are (re)activated by certain types of antigens and start differentiating into antibody-secreting plasma cells. Complete negativity of MUM1 in mantle zone B cells containing naive B cells and their malignant counterpart, MCL, appears to indirectly support this hypothesis. Normal plasma cells both in the lymph nodes and in the bone marrow also showed strong reactivity, which suggests an essential role of MUM1 in maintaining their phenotypes. Analogous to this result, all paraffin-embedded marrow samples derived from the patients with MM showed strong immunoreactivity for anti-MUM1 serum (data not shown). This result was the same as that for cytospin-prepared myeloma cell lines. It is understood from previous reports that MUM1 cooperates with PU.1 in upregulating the activity of Ig kappa () 3Ј and Ig lambda () 2-4 enhancers through its direct interaction on specific DNA motifs, which in turn leads to a high production of immunoglobulins. 8, 9, 11 As for B cell NHL, preliminary studies based on findings obtained from double-color fluorescence in situ hybridization (DCFISH) of the metaphase spreads derived from NHL cases and using PAC-DNA at the MUM1 locus and the IgH locus as probes, estimate the frequency of t(6;14) to be as low as 0.59% (1/170 cases) (personal communication by Dr M Taniwaki from the Kyoto Prefectural University of Medicine and Dr I Miura from the Akita University School of Medicine, Japan). This is in contrast to the relatively high frequency (approximately 21.1%) of t (6;14) found in MM samples. 20 Accordingly, most NHL cases included in this study are considered not to harbor t(6;14), although a vast majority of DLBCL, MZL and B-CLL/SLL showed varying degrees of MUM1 expression, which was absent in MCL and FCL. With the exception of B-CLL/SLL, most NHL cases featuring moderate to strong intensities of MUM1 staining were considered to be of GC or post-GC origin. Therefore, the MUM1 negativity in the MCL and the FCL might be explained in terms of their derivation from their respective MUM1 − normal counterparts, ie naive B cells and dark zone B cells. Among DLBCL cases, positivity or negativity for MUM1 may reflect their origin from light or dark zone B cells, which could lead to a subclassification of these heterogeneous lymphoma subtypes based on their derivations. However, we have so far no explanation for why MUM1 is expressed differently in B-CLL/SLL, which has been generally believed to be derived from naive B cells. One possibility is that MUM1 expression can be induced without passing through the GC. This phenomenon might also be related to the finding that some B-CLL cells can undergo class switching recombination without accompanying somatic mutations of variable regions in the IgH gene, which are generally believed to occur in post GC B cells. 21, 22 Another possible explanation, as proposed by Damle et al, 23 involves the existence of heterogeneous derivations in B-CLL/SLL itself, since it is recognized as having originated from at least two different normal counterparts, ie from naive B lymphocytes (Bm1/Bm2) with a relatively high ratio of CD38 expression and with unmutated Ig variable genes and from memory B lymphocytes (Bm5) with a lower ratio of CD38 expression and with mutated Ig variable genes. 24 We also need to consider the possibility of aberrant MUM1 expression in neoplastic B cells.
Significant fractions of T-NHL, including ATL/L, ALCL and unspecified PTCL, showed strong MUM1 positivity, which cannot be explained simply by the activation of T cells as in the case of ATL/L. Even more interestingly, most HD cases showed strong positivity. As MUM1 expression in normal tissues is restricted to lymphoid and melanocytic lineages, this finding may support the notion of the origin of classical type HD being aberrantly activated lymphoid cells. 25 This MUM1 expression, either physiological or aberrant, found in various NHL phenotypes may represent not only the activated state but also the proliferative activity of neoplastic lymphocytes, as MUM1 plays crucial roles both in cellular growth and in the promotion of Ig production in B cells. 1, 11 Therefore, the clinical difference between MUM1
+ and MUM1
− NHL cases, especially in the DLBCL subtype, needs to be clarified.
